Antiviral activity of angelicin against gammaherpesviruses

Area of Science:

• Virology
• Pharmacology
• Natural Product Chemistry

Background:

• Human gammaherpesviruses, such as Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), are significant pathogens linked to various cancers.
• Limited antiviral therapies exist for effective control of gammaherpesvirus replication.
• Murine gammaherpesvirus 68 (MHV-68) serves as a relevant model for studying human gammaherpesviruses.

Purpose of the Study:

• To investigate the antiviral potential of angelicin against gammaherpesvirus replication.
• To evaluate angelicin's efficacy in inhibiting both MHV-68 and human gammaherpesviruses (EBV, KSHV).

Main Methods:

• Assessed the dose-dependent antiviral activity of angelicin against MHV-68 lytic replication post-viral entry.
• Determined the half-maximal inhibitory concentration (IC50) and half-maximal cytotoxic concentration (CC50) of angelicin.
• Evaluated angelicin's effect on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced lytic replication in EBV- and KSHV-infected cells.

Main Results:

• Angelicin demonstrated significant dose-dependent inhibition of MHV-68 lytic replication, with an IC50 of 28.95μM.
• Angelicin exhibited a high safety profile, with a CC50 greater than 2600μM.
• Angelicin effectively inhibited TPA-induced lytic replication of EBV and KSHV in infected human cells.

Conclusions:

• MHV-68 is a valuable model for screening novel antiviral agents targeting human gammaherpesviruses.
• Angelicin shows promising antiviral properties and can serve as a lead compound for developing new anti-gammaherpesvirus drugs.
• Further research into angelicin-based antivirals could lead to effective treatments for gammaherpesvirus-associated diseases.